For many Ebola virus infection, the symptoms of viral infection after cure, survivors still produce prolonged psychiatric symptoms.
Most of the 82 Ebola survivors in a new study from the world’s largest Ebola outbreak had brain symptoms more than six months after the initial infection. The preliminary results will be presented at the American Academy of Neurology’s 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. The study is part of the larger Prevail III study, which follows patients with prior Ebola virus disease and their close contacts who serve as study controls.
“While an end to the outbreak has been declared, these survivors are still struggling with long-term problems,” said study author Lauren Bowen, MD, of the (NIH) National Institute of Neurological Disorders and Stroke (NINDS) in Bethesda, Md., and a member of the American Academy of Neurology. “More than 28,600 people were infected with Ebola in West Africa during the outbreak. Of that number, 11,300 died. In collaboration with the ongoing PREVAIL III natural history study of Ebola survivors, we wanted to find out more about possible continued long-term brain health problems for the more than 17,000 survivors of the infection.”
For the study, a team of NINDS neurologists examined 82 Ebola survivors from Liberia with an average age of 35 years. At least six months after the start of their disease, most of the survivors had some neurologic abnormality. The most common ongoing problems were weakness, headache, memory loss, depressed mood and muscle pain. Two people were suicidal and one had hallucinations. Common neurological findings on examination included abnormal eye movements, tremors and abnormal reflexes. Controls are in the process of being evaluated to determine which of these findings are Ebola-specific.
“It is important for us to know how this virus may continue to affect the brain long term,” said Bowen.
Related posts:
Allergan Announced That The US FDA Has Approved DALVANCE Supplementary New Drug Application (sNDA)
The completion of the first Phase 2a clinical trial for SYN-004 is an important achievement for Synthetic Biologics
UM SOM Develop a Vaccine To Prevent a Group of Deadly Bacterial Infections
Scientists prove effectiveness of gene editing system in eliminating HIV from DNA of CD4+ T-cells